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Vasoactive intestinal polypeptide ( VIP) and the more recently release induced by the sucking stimulus (10 ), indicating that this peptide stimulates prolactin secretion under physiological condidiscovered pituitary adenylate cyclase-activating polypeptide (PACAP) are related peptides that are thought to have important tions. Experiments on humans and non-mammalian species such as the chicken provide further support for the notion that VIP is roles in regulating pituitary function. At least for some species, there is now considerable evidence implicating VIP as a prolactin a prolactin-releasing factor ( 11, 12). However, perhaps surprisingly, evidence is now accumulating to indicate that, at least in releasing factor. In the rat, VIP is found within the external zone of the median eminence ( 1, 2) , it occurs at high concentrations sheep, VIP is not involved in pituitary function. In this species, VIP is found within the external zone of the median eminence in hypophysial portal blood (3 ) and it stimulates the release of prolactin both in vivo and in vitro (4) (5) (6) . VIP receptors occur in but is not secreted into hypophysial portal blood (13) and, at least in vivo, does not induce prolactin secretion (14, 15 ). In the pituitary gland ( 7) and it is presumably via these receptors that VIP induces Ca2+ influx, and therefore prolactin secretion, contrast to the rat, cAMP is not a second messenger for VIP in sheep pituitary cells (16 ) but whether it influences hormone via cAMP dependent and independent mechanisms (8, 9 ). Furthermore, immunoneutralization of VIP prevents the release secretion in vitro, is not known. The evidence implicating PACAP as a hypophysiotrophic factor of prolactin induced by ether stress and delays the hormone is less convincing than for VIP. PACAP containing fibres are found within the external (sheep, (17 ); human, ( 18)) or internal (rat; (19, 20) ) zones of the median eminence and, at least for the rat, PACAP has been detected in hypophysial portal blood (21 ) . PACAP was named because of its ability to stimulate cAMP accumulation in rat pituitary cells (22), a feature that has now been demonstrated for several species (sheep, (16); frog, ( 23) ) and a number of other cell types e.g. (24, 25) . In addition, other signal transduction pathways such as the inositol phosphate pathway are also used by this peptide ( 26) . In contrast to the unambiguous effects of PACAP on second messengers in pituitary cells, effects on pituitary hormone secretion are less striking. In the rat, peripheral injection of relatively large concentrations of PACAP is needed to stimulate secretion of GH, LH, ACTH and prolactin (27, 28 on FSH secretion ( P<0.05, ANOVA) but no single concentration tested significantly different from the control in the pair-wise The aim of this study was therefore to determine whether PACAP or VIP could influence secretion of several anterior comparisons (Fig. 2) . For both the GH and FSH results, there was a significant interaction (P<0.01) between animal and conpituitary hormones from sheep pituitary cells maintained in static culture. In addition to direct effects on hormone secretion, PACAP centration which indicates the pattern of response to PACAP varied between animals. In contrast to GH and FSH, the concenor VIP could influence anterior pituitary function by interacting with the known hypophysiotrophic factors such as GH-releasing trations of LH and prolactin were not affected by PACAP (results not shown). Potential effects of VIP on prolactin secretion were hormone (GHRH ) or gonadotrophin releasing hormone (GnRH ) or the prolactin release-inhibiting factor dopamine and so this re-evaluated with the 3 h incubations and at a range of concentrations of VIP (1 nmol/l-1 mmol/l ) but irrespective of concentrawas also tested. tion, VIP had no effect on prolactin concentrations (results not shown).
In order to show that the cultured ovine pituitary cells would
Results
respond to proven hypophysiotrophic factors, a limited number Time course and concentration-response experiments of experiments were undertaken with GHRH, GnRH and thyrotrophin-releasing hormone (TRH ). The lowest concentration of In an initial experiment replicated on cells from 4 pituitary glands, the response to PACAP (0.1 mmol/l ) was determined at incubation GHRH to significantly (P<0.01) stimulate GH secretion was 10 pmol/l for which GH concentrations were 170±10% of the times of 0.5, 1, 2, 3, 4, 6, 12 or 24 h, with control and peptide treated incubations terminated at each time point. In the absence vehicle treated control (n=6). For GnRH, FSH and LH secretion were stimulated at concentrations greater than 100 pmol/l. At of PACAP, the concentration of prolactin, GH, LH, and FSH in the culture medium increased with time which indicates constituthis concentration LH and FSH concentrations were 425±88 (n=6) and 161±49% (n=4) of the control. A complete concentive secretion of hormone from the respective pituitary cell type. In the presence of PACAP, GH concentrations were significantly tration-response curve was not determined for TRH but at a concentration of 10 nmol/l, prolactin concentrations increased to (P<0.01) increased between 0.5 h and 4 h ( Fig. 1) . Thereafter GH concentrations remained above control values, although this 361 and 533% (means of 2 separate experiments) of control values. difference was only significant at the 12 h incubation ( P<0.01).
Interaction between PACAP and hypophysiotrophic factors For prolactin, LH and FSH, PACAP had no significant effects at any time point. In a similar experiment with VIP (0.1 mmol/l ),
To determine whether the GH response to GHRH was affected by PACAP, ovine GHRH (30 pmol/l ) was incubated with or cells from two pituitary glands were studied independently and in neither case did VIP treatment affect the concentration of GH, without increasing concentrations of PACAP ( 1 nmol/l-1 mmol/l ) for 3 h. The results pooled from 4 separate experiments show prolactin, LH or FSH in the culture medium.
Based on the above results, the response to a 3 h incubation that, as expected, GHRH (30 pmol/l ) stimulated (P<0.01) the basal secretion of GH to 194% of the control (Fig. 3 ) . PACAP with increasing concentrations of PACAP ( 1 nmol/l-1 mmol/l ) was tested. The results in Fig. 2 are pooled from 6 separate also stimulated GH secretion but only at high concentrations (0.1 and 1 mmol/l ) was the effect significant (P<0.05 and P<0.01 effect on LH secretion but caused a small increase in FSH secretion ( P<0.05, ANOVA) with the highest concentration respectively). When PACAP was coincubated with GHRH, the highest concentration of PACAP (1 mmol/l ) significantly reduced (1 mmol/l ) significantly increased over the control (Fig. 3 ). Co-incubation of PACAP with GnRH had no effect on either the the GH response to GHRH (P<0.05). At lower concentrations, PACAP increased the response to GHRH but this effect was not LH or FSH responses to GnRH. The next experiment was performed to investigate the effects significant.
A similar design was used to test for interactions between of PACAP on prolactin secretion during a period of dopaminergic inhibition. Cells were incubated with PACAP ( 1 nmol/l-1 mmol/l ) PACAP and GnRH (30 pmol/l ). As expected, GnRH caused an increase in LH and FSH concentrations to 353 and 171% of the for 3 h in the presence or absence of dopamine (0.1 mmol/l ) with the entire experiment replicated on 4 separate occasions. control respectively. In the absence of GnRH, PACAP had no Dopamine suppressed prolactin concentrations to 38% of the control and this effect was the same irrespective of whether PACAP was added to the incubation medium. In incubations receiving PACAP alone, mean prolactin concentrations increased with concentration but this effect was not significant (results not shown).
Antagonist experiments
The PACAP antagonist, PACAP( 6-38), was tested for its ability to antagonize the GH response to PACAP. Cells were incubated for 3 h with increasing concentrations of PACAP (1 nmol/l-1 mmol/l ), with or without 1 mmol/l PACAP( 6-38). The results from one of two identical experiments in Fig. 4 show that, as expected, the 0.1 and 1 mmol/l concentrations of PACAP significantly (P<0.05) increased GH concentrations. PACAP antagonist ( 1 mmol/l ) alone had no effect on GH secretion but when coincubated with PACAP, it prevented the GH response to PACAP. When the experiment was repeated on cells from another animal, qualitatively similar results were obtained.
In an earlier experiment, PACAP (1 mmol/l ) inhibited the GH response to GHRH. However PACAP at the same concentration also stimulates GH secretion. It is possible therefore that PACAP may be a partial agonist at the GHRH receptor. In order to test performed in which cells were incubated for 3 h with GHRH (30 pmol/l ), with or without GHRH antagonist (10 nmol/l ) or medium alone (control ). The results in Fig. 5 show that the GHRH antagonist had no effect on GH secretion. As expected, PACAP alone stimulated GH secretion with only the highest concentration (1 mmol/l ) significantly different ( P<0.05) from the control. Coincubation of GHRH antagonist with PACAP had no significant effect on the GH response to PACAP. GHRH alone stimulated GH secretion to approximately 170% of the control value (P<0.01). This response was partially ( P<0.05 compared with GHRH ) inhibited by the GHRH antagonist although GH concentrations were still elevated compared with the control (P<0.01). When the experiment was repeated on cells from another animal, qualitatively similar results were obtained. Finally, we wished to determine whether the GH response to PACAP was mediated by cAMP. Rp-cAMPS, a competitive antagonist of cAMP on cAMP-dependent protein kinase A (32, 33), was used to block cAMP-mediated effects subsequent to stimulation by PACAP. For comparison, the effect of Rp-cAMPS on the GH response to GHRH was also determined. Cells were preincubated with or without Rp-cAMPS ( 10 mmol/l ) for 30 min after which they were incubated with PACAP (1 mmol/l ) or GHRH ( 30 pmol/l ), with or without Rp-cAMPS (10 mmol/l ) for 3 h. The results in Fig. 6 show that both GHRH and PACAP significantly increased (P<0.01) GH concentrations and Rp-cAMPS had no effect by itself. However, in the presence of the GH response to PACAP. Cells were incubated for 3 h with increasing
Rp-cAMPS, the GH response to GHRH was reduced (P<0.05, concentration of PACAP, with (#) or without ($) PACAP compared to GH response to GHRH ) but still remained signifi- Rp-cAMP had no effect on the GH response to PACAP. Similar secretion whereas GHRH was effective at much lower concentrations ( 0.1 pmol/l ). PACAP also affected FSH secretion in the PACAP concentration-response study although, as with GH, the response was small and only occurred at high concentrations in comparison with the FSH response to GnRH. There were also differences in responsiveness when the treatments were replicated on cells from different sheep. In the concentration-response study based on pituitaries from 6 ewes, the overall effect of PACAP in the ANOVA was significant but, based on the pairwise comparisons with the control, no concentration was significantly increased from the control values. Four of these sheep were also used in a later experiment and, when analysed separately for this study, the highest concentration of PACAP did indeed stimulate FSH secretion. In addition to those factors considered above for GH, the variation in responsiveness to PACAP observed here for FSH might also be due to differences in reproductive status of the animals used in the various replicates which were done at different times of year and without regard for stage of the oestrous cycle.
The effects of PACAP on GH and FSH secretion in the present study only occurred at very high concentrations which are unlikely to be in the physiological range. To date, PACAP has only been detected in hypophysial portal blood from the rat where it occurs in concentrations of 50-100 pmol/l (21) pituitary could receive high concentrations of PACAP via the short hypophysial portal veins. Nevertheless, it seems unlikely that such high concentrations of peptide as were required in the results were obtained when the experiment was repeated on cells from a second ewe. present in vitro study could be achieved via this route. It is also possible that the high concentrations required to evoke hormone secretion in the present study could be due to Discussion features of the in vitro system. For example, desensitization to PACAP could reduce the responsiveness of cells maintained in In this study, the effects of PACAP and VIP on GH, prolactin, LH and FSH secretion from sheep pituitary cells in primary static culture and indeed we have observed such an effect in terms of the cAMP response to PACAP (16 ). Alternatively, the GH culture were examined. The only significant response to be observed in the time-course studies was an increase in GH response to PACAP may be indirect due to release of some paracrine or autocrine substances. Once secreted, these would be concentrations induced by PACAP between 1 and 4 h of incubation and again at 12 h. In further experiments based on a 3 h diluted by the incubation medium, thereby necessitating high concentrations of PACAP to induce effective concentrations. The incubation, it was shown that only high concentrations of PACAP (0.1 and 1 mmol/l ) gave a significant GH response. This experisecretion and effects of such substances have yet to be identified. Both PACAP and GHRH stimulate intracellular cAMP proment was repeated on 6 animals at different times of the year and, as shown by the significant interaction between concentration duction and, at least for GHRH, cAMP is known to be an important second messenger involved in the GH secretory and animal in the ANOVA, the responsiveness to PACAP varied between animals. This suggests that factors such as variations in response ( 35) . However, the eventual stimulus for GH secretion from the somatotroph is an elevation in intracellular Ca2+ laboratory technique, genetic variation between individuals or physiological state (e.g. seasonal effects, nutrition etc) of the concentration due to influx of extracellular Ca2+ ( 36, 37) . In rat somatotrophs, GHRH induces Ca2+ influx by several mechananimal before euthanasia could influence the in vitro responsiveness of pituitary cells to PACAP. The lowest concentration of isms. Binding of GHRH to its receptor is known to activate adenylate cyclase resulting in increased intracellular cAMP. PACAP that stimulated GH concentrations was more than three orders of magnitude greater than that required by GHRH and cAMP then binds to and activates protein kinase A ( PKA) which then phosphorylates calcium channels allowing them to open even at these large concentrations of PACAP, the GH response was relatively small. Similar observations have been made in during depolarisation (38, 39 ) . There are also mechanisms which link the activated GHRH receptor to Ca2+ influx and which are dispersed pituitary cells from rats (22, 29) and cattle ( 34) in which concentrations of PACAP above 1 nmol/l increased GH independent of cAMP. For example, GHRH also activates PKC to stimulate GH secretion (40 ) and the GTP-binding protein Gs, from any ovine tissues but in rats, 3 groups of PACAP/VIP receptors (PVR) have now been identified and cloned and all 3 which is stimulated through activation of GHRH receptors by GHRH, may open calcium channels by membrane-confined mechsubtypes occur in the anterior pituitary gland (see (46) for a review). PVR 1 which is also known as the PACAP type-I anism (39, 41) . Much less is known about the mechanisms through which PACAP induces GH secretion. In rat somatoreceptor is characterized by high affinity for PACAP, much lower affinity for VIP and coupling with adenylate cyclase and trophs, PACAP causes an influx of Ca2+ which can be blocked by Rp-cAMPS (42). These findings suggest that PACAP causes phospholipase-C. PVR 2 and PVR 3 (also known as PACAP/VIP type II binding sites), have similar affinities for PACAP and VIP GH secretion by increasing intracellular cAMP and activating PKA. However, in the present study based on a mixed pituitary and couple with adenylate cyclase. It is generally thought that PACAP stimulates GH secretion from rat somatotrophs by acting cell population from the ewe, Rp-cAMPS had no effect on the GH response to PACAP. As a positive control we showed that on either PVR 2 or 3 subtypes coupled to adenylate cyclase (46 ) . This has been proven for GH3 cells ( 47) but, to our knowledge, Rp-cAMPS partially inhibited GH secretion stimulated by GHRH. This result is consistent with the above information that not for rat somatotrophs. In contrast in the ewe, we have shown here that VIP does not stimulate GH secretion and that cAMP GHRH uses the cAMP/PKA signal transduction system to stimulate GH secretion. Because GHRH also uses other signal transducis not involved in the GH response to PACAP. In an earlier study we also reported that PACAP but not VIP is linked with adenylate tion pathways, Rp-cAMPS is only partially effective in blocking the GH response. Our observation that the GH response to cyclase in this species. Assuming that sheep have similar PVR subtypes to the rat, these results suggest that PACAP influences PACAP was not blocked by Rp-cAMPS suggests that, at least in the ewe, PACAP uses signal transduction pathways other than GH secretion via a PVR 1 subtype. However, it is also possible that the hormone secretory responses observed in the present the cAMP/PKA system to stimulate GH secretion. Further support for this notion comes from the observation that the study could be due to cross-reaction between PACAP and some other type of receptor. lowest concentration of PACAP able to stimulate cAMP accumulation in sheep pituitary cells is 2 orders of magnitude below that
The failure of VIP to stimulate prolactin secretion in sheep pituitary cells is in direct contrast to studies in the rat, human required to stimulate GH or FSH secretion (16 ).
Possible interactions between PACAP and GHRH, GnRH or and chicken (4, 11, 12 ) in which VIP is a prolactin-releasing factor. However the lack of effect of VIP on prolactin in vitro is dopamine were also investigated in this study. Clearly PACAP did not modify the prolactin response to dopamine or the LH consistent with in vivo studies of the ewe (14, 15) in which intracarotid or intravenous administration of VIP had no effect on response to GnRH. Although, PACAP stimulated a small increase in FSH secretion at the highest concentration tested, this effect plasma prolactin concentrations. In addition, it has been recently shown that VIP is not secreted into hypophysial portal blood was not additive or antagonistic to the GnRH effects on FSH secretion. The only marked interaction that was observed was (13) of the ewe. Taken together, these studies now provide convincing evidence that this peptide is not a prolactin releasing the antagonistic effect of PACAP on GHRH induced GH secretion which has not been previously observed in any species. This factor in sheep.
In conclusion, these experiments on dispersed sheep pituitary inhibition which occurred consistently in 4 separate experiments but only at the highest concentration of PACAP ( 1 mmol/l ), cells show that PACAP stimulates GH and FSH secretion but only at concentrations well above the expected physiological could occur by many mechanisms. First, PACAP may be a partial agonist at the GHRH receptor but with low affinity and so range. No evidence was obtained to suggest that PACAP may augment the secretory response to GnRH, GHRH or dopamine. effectively acts as an antagonist when co-incubated at high concentrations with GHRH. PACAP, VIP and GHRH belong to
Results from experiments with several antagonists along with the observation that VIP had no effect on GH secretion suggest that a superfamily of structurally related peptides ( 22, 43 ) and evidence of cross-reaction between various ligands and receptors does exist PACAP influences GH via a PVR 1 linked to a second messengers other than cAMP. These experiments also confirm that VIP is (44). Binding of PACAP to GHRH receptors is therefore possible and so in the present study, a GHRH antagonist was tested for not a prolactin releasing factor in this species. its ability to block the GH response to PACAP. The GHRH antagonist, at a concentration which inhibited the GH response
Materials and methods
to GHRH, did not affect the GH response to PACAP suggesting that PACAP does not stimulate GH secretion via the GHRH Reagents receptor which is in accord with similar experiments done on rat
The synthetic peptides PACAP and VIP were purchased from the Peptide pituitary cells (45 ) . It is obvious that a similar result at higher Institute Inc. (Osaka, Japan) and had identical amino acid sequences to concentrations of the GHRH antagonist would be more convinthe native ovine peptides. PACAP and ovine GHRH were purchased from Peninsula (Belmont, CA, USA). GnRH and dopamine were cing. However the GHRH antagonist is a partial agonist at higher purchased from Sigma Chemical Co. (Castle Hill, NSW, Australia). (Nconcentrations and so such an experiment could not be under- 
